Exact Sciences Corporation (NasdaqCM:EXAS)'s Chief Executive Officer, Kevin Conroy recently stated, "We're making these investments now for growth in the future. We've also invested in strategic acquisitions. The most recent are bioscience, which has a library of advanced cancer markers that we think will complement our DNA methylation markets. And so we will continue to look at opportunities to acquire new technologies and companies that can help fuel our growth and meet our demand."